Hemogenyx Pharmaceuticals PLC on Friday said it has completed the final development run for its manufacturing process of HEMO-CAR-T cells.

The London-based biopharmaceutical group develops new therapies and treatments for deadly blood diseases.

It has now completed the second and final run of the end-to-end development process for the HEMO-CAR-T cells, which was carried out at Hemogenyx’s current Good Manufacturing Practice compliant clean rooms.

Hemogenyx said this is another step in preparing for its application for the treatment to be labelled as an Investigational New Drug.

The US Food and Drug Administration will review the application and decide whether to authorise the commencement of Phase I clinical trials of HEMO-CAR-T.

Hemogenyx’s team of scientists is now moving toward engineering runs of HEMO-CAR-T cell production.

Hemogenyx shares were up 6.7% to 1.36 pence on Friday afternoon in London.

Copyright 2022 Alliance News Limited. All Rights Reserved.